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A B S T R A C T
Objective: The study compared the preferences of patients and health-care professionals
for the key attributes of a pharmacogenetic testing service to identify a patient’s risk of
developing a side effect (neutropenia) from the immunosuppressant, azathioprine.
Methods: A discrete choice experiment was posted to a sample of patients (n309) and health-
care professionals (HCPs) (n410), as part of the TARGET study. Five attributes, with four levels
each, described the service as follows: level of information given; predictive ability of the test;
how the sample is collected; turnaround time for a result; who explains the test result. Data
from each sample were first analyzed separately and responses were compared by 1) identify-
ing the impact of the scale parameter, and 2) estimating marginal rates of substitution.
Results: The final analysis included 159 patients and 138 HCPs (50% & 34% response rates).
Estimated attribute coefficients from the patient and HCP sample differed in size, after
taking into account the impact of the scale parameter. Patients and HCPs had similar pref-
erences for predictive accuracy of the test and were willing to wait 2 days for a 1% improve-
ment in test accuracy. Patients preferred to obtain more information and were willing to
wait 19 days compared to 8 days for HCPs for providing higher levels of information.
Conclusions: Patients demanded accurate and timely information from health-care pro-
fessionals about why it was necessary to have a pharmacogenetic test and what the test
results mean. In contrast, health-care professionals appear to focus more exclusively or
entirely upon the predictive accuracy and waiting time for a test result.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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122 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4ntroduction
harmacogenetic tests rely on the premise that data on vari-
tion in specific (known) genes can provide clinicians with
nformation about an individual’s ability to absorb, distribute,
etabolize, and excrete a drug, or to indicate tumor suscepti-
ility to a particular chemotherapy. Such data can guide pre-
cribing by providing information about the probability that
n individual will have a therapeutic response, or develop side
ffects. In principle, pharmacogenetic testing offers potential
enefits by helping clinicians to personalize prescribing so pa-
ients may benefit from improvements in health without ex-
eriencing harmful side effects. Although suggested as a tech-
ology for the future [1], there are already examples of
harmacogenetic tests being recommended and used in
ealth-care systems [2]. Pharmacogenetic tests associated
ith chemotherapy are cited as the most clinically relevant
xamples [3], but other examples of tests being used in main-
tream health care exist [4–6].
Widespread introduction of pretreatment testing will use
carce health-care resources associated with setting up and
unning a pharmacogenetic service. There are limited numbers
f economic evaluations of pharmacogenetic tests [7] providing
nformation on the relative costs and benefits of using technol-
gies to generate genetic data to inform prescribing. Decision
akers charged with commissioning pharmacogenetic tests
ill also need information on the appropriate configuration of
harmacogenetics services in mainstream health care, and
ssociated training requirements, to meet the challenges of
elivering a timely, safe, effective, and efficient service [8].
his considered approach is necessary to move from diffusion
passive spread) of an innovation to implementation (active
nd planned efforts to mainstream an innovation within an
rganization) [9].
The thiopurine methyltransferase (TPMT) test is a good ex-
mple of a pharmacogenetic test currently being recom-
ended for use in clinical practice and has been revealed to be
potentially useful means of identifying people at risk of pro-
ound neutropenia from azathioprine [10]. Azathioprine is an
ffective treatment used for a number of autoimmune condi-
ions, such as rheumatoid arthritis (RA), inflammatory bowel
isease (IBD), and after organ transplantation [11–14]. The ef-
ectiveness of azathioprine is limited by a number of serious
ide effects, including profound neutropenia, which puts pa-
ients at risk of life-threatening infections and death [9]. The
rimary aim of the TPMT test is to identify the activity of the
PMT enzyme, which metabolizes azathioprine to its active
nd inactive metabolites in the body, and indicate a person’s
isk of profound neutropenia. Two analytical methods of offer-
ng the TPMT test measure either enzyme activity (or phenotype)
r variants in the TPMT gene of the patient (genotype). TPMT
nzyme measurement is technically challenging and can be dis-
orted following blood transfusion. Genotyping commonly in-
olves looking for the three variant alleles, TPMT*2, TPMT*3A,
nd TPMT*3C, that account for 80% to 95% of intermediate or low
ctivity cases. Genotyping for the common TPMT variants is
echnically straightforward but, unlike enzyme measurement,ay not identify all TPMT deficient individuals. Concordance cate between TPMT genetics and phenotypes is around 98%.
enotyping and phenotyping have similar costs [15].
The TPMT test is suggested as a potentially useful test in a
umber of clinical guidelines in the United Kingdom [16,17],
lthough in the UK, the enzyme-level measurement test is
urrently used in preference to the genotype (DNA-based) test
18,19]. Prospective trials suggest support for pretreatment
PMT testing in terms of clinical utility [20,21], defined broadly
s how the results of the test can be used to inform clinical
ecision making [22]. Economic modeling studies suggest the
PMT test is a cost-effective use of health-care resources [23].
robust evidence base showing clinical utility is a necessary
ut not sufficient prerequisite for the successful implementa-
ion of pharmacogenetics into practice. Clinicians must use
uch evidence and change their prescribing behavior to max-
mize patient benefits from pharmacogenetic testing. Health-
are professionals involved with pharmacogenetic service de-
ivery will need to understand the probabilistic nature of the
nformation that a pharmacogenetic test will provide: when it
s appropriate to test patients; how and from where should
articular tests be ordered; how to engage patients in the de-
ision about whether to test; and how much information to
ffer during the prescribing decision-making process. It is vi-
al that relevant health-care professionals can interpret a
harmacogenetic test result, decide on the appropriate treat-
ent strategy, and involve the patient in this process.
Laboratories within the British National Health Service
NHS) are providing pharmacogenetic tests [24]. A number of
otential service delivery models could exist but these are yet
o be described explicitly. In the UK, four priority groups have
een identified who need to be prepared for moving pharma-
ogenetics into mainstream health care: medical practi-
ioners, nurses, dieticians, and pharmacists [25]. However, to
ate, there has been no work that systematically evaluates
ow pharmacogenetics will be provided as part of main-
tream health-care services [26]. Fargher et al. [26] explored
he views of patients and health-care professionals concern-
ng pharmacogenetic services and their future delivery. In this
ualitative study, pharmacogenetics was perceived to be of
enefit to both groups. Patients expressed a desire to receive
imely and clear information from an educated health-care
rofessional who explains the reason for taking the test and
nabled confident interpretation of the result. None of the
ealth-care professionals questioned expected to have re-
ponsibility for the future delivery of clinical pharmacogenetic
ervices. Genetic specialists believed that pharmacogenetic
esting should form part of mainstream health-care services
ather than involving the regional specialist genetic service. In
ontrast, non-genetics health-care professionals did not feel
hey had the relevant knowledge or skills to offer advice on a
harmacogenetic test.
Stated preference methods can be usefully applied to in-
orm the development of new models of service delivery [27].
iscrete choice experiments (DCEs) are a particularly useful
orm of stated preference method because they can identify
he trade-offs that individuals make between the process and
utcome-focused attributes of a new service [28]. Health care
s characterized by asymmetry of information between clini-
ians, “the experts,” and patients who “consume” services and
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123V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4reatments to improve their health. Clinicians act as agents
or their patients. This study aimed to identify and compare
he preferences of patients and health-care professionals for
he key attributes of an example model of a pharmacogenetic
esting service. The study focused on one example of a phar-
acogenetic test that is currently recommended for use in
linical practice, the pretreatment TPMT test for azathioprine;
owever, no standards for service delivery currently exist.
ethods
postal DCE was designed to identify and compare the pref-
rences of patients and health-care professionals for at-
ributes of a pharmacogenetic testing service. The DCE used a
pecific case study of a pharmacogenetic test currently being
sed in clinical practice: the TPMT test to inform azathioprine
rescribing in autoimmune conditions. Clinical guidelines
nd some regulatory bodies have already made strong recom-
endations that TPMT testing should be used prior to starting
zathioprine, or other thiopurine-based, medicines. There-
ore, the choice question was framed as: what are the pre-
erred characteristics of a pharmacogenetic service? The DCE
sed generic attributes common to both alternatives (unla-
eled design) and did not include an opt-out option. An alter-
ative policy question would be to consider potential uptake
f an intervention given the model of service delivery. This,
owever, assumes that patients are in the position to make a
hoice about whether to have a pharmacogenetic test, which
s in effect, a diagnostic aid.
stablishing attributes and levels
he attributes and levels (see Table 1) were developed using
Table 1 – Attribute names and description.
Attribute name Attribute description
Information The level of information given to the pat
about the test
Predictive accuracy The ability of the test to predict the risk o
the side effect (neutropenia)
Sample How the sample is collected
Turnaround time How long it takes before the patient rece
the result
Explanation Who explains the result to the patient
GP, general practitioner.hree synergistic approaches. A review of the literature was ponducted to understand the key outcomes important for a
harmacogenetic test. A qualitative study was then specifi-
ally designed to inform the selection and wording of at-
ributes and levels in this DCE (see Fargher et al. [26] for the
esign and analysis of this study). In brief, the study used a
ombination of focus groups with health-care professionals
n17) and semistructured interviews with patients (n25) to
dentify the key aspects to consider when designing a phar-
acogenetic service. This exercise generated 17 themes,
hich were independently reviewed by two members of the
esearch team (E.F. and K.P.). Themes relevant to the framing
f the choice question were considered to fall into five inde-
endent categories, which were converted into plausible at-
ributes and levels. Finally, an expert panel comprising 10
embers of the TARGET study team (three clinicians, three
ealth economists, two health service researchers, one stat-
stician, one pharmacist) were asked: 1) Do you agree with
he selection of attributes? 2) Are there any attributes miss-
ng? 3) Do you agree with the levels? and 4) How should we
hrase the attributes and levels?
The DCE included two “value” attributes, predictive accu-
acy and turnaround time, to allow comparison across respon-
ent samples by calculating marginal rates of substitution.
ost had to be excluded as an attribute because of recommen-
ations by the ethics committee. The level range for each at-
ribute was set to represent clinically meaningful options and
e sufficiently wide to encourage respondents to take account
f each attribute and limit the possibility of dominant prefer-
nces. This consideration was particularly important for the
wo value attributes. There is little empirical evidence to sup-
ort the ideal number of levels for an attribute in a choice
xperiment. Ratcliffe and Longworth [29] investigated the
tructural reliability of a DCE within health technology assess-
ent and concluded that there was evidence to support a
Levels
(coding for analysis)
Effects coding
None Information-none (base)
Low Information-low
Moderate Information-mod
High Information-high
50% (50) Predictive accuracy-50 (base)
60% (60) Predictive accuracy-60
85% (85) Predictive accuracy-85
90% (90) Predictive accuracy-90
Blood test Sample-blood (base)
Mouthwash Sample-wash
Finger prick Sample-finger
Mouth swab Sample-swab
2 days (2) Turnaround time-2 (Base)
7 days (7) Turnaround time-7
14 days (14) Turnaround time-14
28 days (28) Turnaround time-28
GP Explanation-GP (base)
Pharmacist Explanation-pharmacist
Hospital doctor Explanation-hospital doctor
Nurse Explanation-nurseient
f
ivessychological effect of the number of attributes affecting the
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124 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4elative importance that respondents place on a particular at-
ribute. For this reason, this DCE was designed such that each
ttribute had the same number of levels (four), which also
esults in level balance.
xperimental design
our levels for each of the five attributes result in 1024 (45)
ossible scenarios, which were reduced to a manageable
umber of scenarios for each respondent using a fractional
actorial design. The design was identified using catalogues of
rthogonal arrays with 16 scenarios, five attributes, with four
evels, including main effects only (see design oa.16.5.4.2) [30].
he binary choice sets were then created using Street and
urgess (2007) methods [31]. Online software was used to
heck that the design could estimate main-effects and com-
are the design efficiency with the optimal design for a choice
et with two alternatives. The design was 94.5% efficient [32].
ne version of the survey was created that contained 16
hoice binary sets (Fig. 1).
onstructing the survey
he questionnaire was piloted on a convenience sample of 20
atients attending the clinic, while they were being recruited
o the TARGET RCT, and 30 staff at the University of Manches-
er: to assess whether respondents could understand the task,
he length and time to complete the survey, and the face va-
idity of the attributes and level phrasing. The final design of
he survey comprised five sections. To increase the chance of
espondents understanding the purpose of the DCE, and de-
rease the chance of irrational responses, the first section of
he survey provided respondents with a “training module”
hat contained information about the role of TPMT testing in
zathioprine prescription and a description of the attributes
nd levels at the start of the questionnaire. In addition, a sep-Fig. 1 – Example of a binarate information sheet, which repeated the page in the sur-
ey describing attributes and levels but with a larger font size,
as also inserted into the survey to allow respondents to con-
inually refer to full definitions of each attribute and level
hile they completed each question in the survey [33]. The
ve attributes were presented in the order they would be ex-
erienced when accessing the service. This same order was
sed for every exercise. Section two involved a ranking exer-
ise where respondents were asked to rank the attributes in
rder of preference from one to five. Section three included a
uestion on each attribute that asked respondents to indicate
heir preferred level, out of the four levels defined, for each
ttribute. Section four contained the DCE task and section five
ncluded questions about the respondents and some back-
round questions on whether they had been given (or used) a
harmacogenetic test, experienced a side effect from a medi-
ine themselves, or if a family member had experienced a side
ffect.
ample frame and administering the survey
he sampling frame included patients prescribed azathio-
rine and health-care professionals with experience of pre-
cribing and advising on azathioprine. The DCE was con-
ucted alongside a prospective randomized controlled trial
the TARGET study). Patients were recruited to the TARGET
tudy (October 2005 to December 2007) from gastroenterology
r rheumatology clinics at 19 participating study centers, pre-
ominantly based in the Northwest of England. Following eth-
cal approval, the DCE was posted in January/February 2008
with two reminders) to a sample (n309) of patients with
astroenterology- or rheumatology-related conditions. This
ample had been recruited to the TARGET study which was
esigned to identify the clinical utility and cost-effectiveness
f the TPMT test to inform azathioprine prescribing. A DCE
ith the same design was posted to a sample (n410) ofry choice question.
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125V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4ealth-care professionals, comprising hospital consultants,
urses, general practitioners (GP), and pharmacists, who had a
ole in the management of patients in the TARGET study. All
uestionnaires were posted after the last patient was re-
ruited to the trial.
ata analysis
he aim of the data analysis was to identify the main effects
or each attribute. The base-case analysis ran two separate
odels for each sample: patients and professionals. Data
ere analyzed using the random effects probit model to ac-
ount for repeated observations from the same respondent:
it01info2pred3sam4time5explii,t
it is a binary variable (choose a or b) that assumes individuals
choose the alternative for choice t that leads to higher levels
f utility
0 is the constant term
Bx are the estimated parameters for the attributes
i is the error term representing between individuals, i
it is the traditional error term unique to each observation,
within individuals, i
The qualitative data were effects coded for the analysis
see Table 1). Using effects coding means that the estimate of
he omitted variable of an effects-coded attribute is equal to
inus one multiplied by the sum of the estimated levels. The
alue attributes were included in the base-case analysis as a
inear, continuous variable. A secondary analysis explored the
ssumption of linearity in both value attributes by 1) effects
oding the value attributes and plotting the resulting size of
he attributes against the level for each attribute, and 2) re-
unning the model including an additional quadratic term for
ach value attribute.
ominant preferences
espondents have been shown to sometimes exhibit lexico-
raphic preferences when competing DCEs. This means the
espondents make their choices by considering the attributes
n a (predefined) order of priority rather than trading between
he attributes. This implies non-compensatory decision mak-
ng and means that the axioms of random utility theory and
ancaster’s consumer theory do not hold [34]. This would
ean that marginal rates of substitution between attributes
ave no meaning in this context [35]. Dominant preferences
re one type of lexicographic preferences. The presence of
ominant preferences in this study was explored using the
pproach taken by Scott [35]. Scott uses Lancaster’s [36] defi-
ition of dominance, “A characteristic is dominant within
ome group of characteristics, in some set of situations, if the
onsumer always prefers a collection with more of the domi-
ant characteristic, whatever the amounts of the other char-
cteristics.” This study explored dominant preferences for the
uantitative attributes (predictive ability and turnaround
ime) and one qualitative attribute (information) where a clear
irection of preferred preference could reasonably be as-
umed. Two approaches were used. Firstly, each of these three ettributes was examined in turn, and a dominant preference
as defined if the respondent always chose the scenario with
he best level for that attribute, then this is a dominant pref-
rence for that attribute. Secondly, ranking data obtained
rom section two of the survey, which asked respondents to
ank the attributes in order of preference (from 1 being most
referred to 5 being least preferred), were combined with the
nformation on the direction of preference. The random ef-
ects probit model was then estimated using data from all
espondents, including those with dominant preferences, and
hen re-run excluding patients who showed dominant prefer-
nces. Coefficients and 95% confidence intervals were com-
uted for the model with and without dominant preferences
nd the results were compared.
alidity
he validity of the model was assessed in two ways. Face va-
idity was identified by checking the sign of the estimated pa-
ameters accorded with a priori expectations. A positive sign
ould be anticipated for predictive ability, which means that
espondents prefer greater predictive ability. Turnaround
ime for a result may be expected to have a negative sign, with
espondents preferring to receive the results of the test more
uickly. An explicit test for internal validity was also included
n the design of the DCE, with an additional question added
hat held the levels of the qualitative attributes (information,
ample collection, explanation) constant but showed a clear
referred direction for the two quantitative attributes with a
igher level of predictive ability and shorter turnaround time.
he impact of including responses from the respondents who
failed” this test for internal validity was assessed by estimat-
ng the random effects probit model including and excluding
hese respondents and comparing the estimated effect sizes
direction and size of the parameters).
xploring the impact of patient and professional
haracteristics on preferences
he background questions, collected in section five of the sur-
ey, were used to conduct a preliminary analysis to explore
hether the characteristics of the patients or health-care profes-
ionals had an impact on preferences. In the patient sample, the
mpact of the following characteristics on preferences was ex-
lored: presenting condition (gastroenterology or rheumatolo-
y); level of education (degree level and equivalent or above; or
o degree); had a pharmacogenetic test (self-reported); reacted
adly to a medicine; member of the family has reacted badly to a
edicine; taken azathioprine; reacted badly to azathioprine. In
he health-care professional sample, the impact of the following
haracteristics on preferences was explored: discipline (hospital
octor, GP, pharmacist, nurse); clinical specialty of respondent
gastroenterology, rheumatology, renal medicine, dermatology);
sed a pharmacogenetic test; reacted badly to a medicine; mem-
er of the family has reacted badly to a medicine. These analyses
ere run separately for the patient and health-care professional
ample data and included covariates in the model as interaction
erms of the attribute and characteristics. The goodness of fit for
ach model with and without these interaction terms was tested
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126 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4sing the likelihood ratio test with a P value threshold of statis-
ical significance set at P 0.01 to allow for multiple testing.
omparing patients’ and professionals’ preferences
he preferences of patients and professionals were compared
sing two approaches: 1) identifying the impact of the scale
arameter, and 2) estimating marginal rates of substitution
ith time and predictive ability as the value attributes.
Comparisons between DCEs that have been generated from
wo data sources, for example, a sample of patients and health-
are professionals, need to take account of differences in unob-
erved variability between the data sources and take account of
Table 2 – Patient characteristics.
Characteristic
Condition
Occupational status
Highest level of education obtained
Ever had a pharmacogenetic test (self-reported)
Ever reacted badly to a medicine (self-reported)
Friends or family ever reacted badly to a medicine (self-reported)
Ever taken azathioprine (self-reported)
Side effects from azathioprine (self-reported)
Treated in hospital for side effects from azathioprine (self-reported)
Always take the dose as prescribed by your doctor (self-reported)GCSE/O, general certificate of secondary education/ordinary level; NVQ, nahe possible effect of this scale parameter [37]. To identify the
mpact of the scale parameter, step one was to plot the estimated
oefficients from each sample against each other on a scatter
lot, to visualize whether the differences are purely due to a
caling effect. A strong linear relationship will indicate that any
ifference in the magnitude of the coefficients is explained by
he scale parameter and differences in scale between the data
rom patients and health-care professionals. The Swait and Lou-
iere [38] test was then used to formally test whether the true
arameter coefficients are significantly different.
Calculating the marginal rate of substitution (MRS), using a
alue attribute, was used as an alternative means of overcoming
he issue of the scale parameter that does not allow direct com-
Number (%) (n159)
Rheumatology 18 (11)
Gastroenterology 141 (89)
Employed full-time 57 (36)
Employed part-time 23 (14)
Self-employed 11 (7)
Unemployed 12 (8)
Retired 39 (24)
Homemaker 7 (4)
Student full-time 8 (5)
Missing data 2 (2)
Postgraduate 5 (3)
Degree 34 (21)
Diploma/NVQs, etc. 21 (13)
A-level 13 (8)
GCSE/O-level 49 (31)
No formal qualifications 14 (9)
Missing data 23 (15)
Yes 33 (21)
No 40 (25)
Do not know 74 (46)
Missing data 12 (8)
Yes 75 (47)
No 78 (49)
Do not know 6 (4)
Missing data 0
Yes 27 (17)
No 126 (79)
Do not know 0
Missing data 6 (4)
Yes 148 (93)
No 6 (4)
Do not know 5 (3)
Missing data 1 (1)
Yes 81 (51)
No 65 (41)
Not applicable 11 (7)
Missing data 2 (1)
Yes 9 (6)
No 72 (46)
Not applicable 75 (47)
Missing data 3 (2)
Yes 136 (86)
No 6 (4)
Not applicable 10 (7)
Missing data 7 (4)tional vocational qualification.
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127V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4arison of estimated parameters from two data sources. The
cale parameter does not affect the ratio of any two coefficients.
he MRS was calculated by dividing the estimated parameter
oefficient for the attribute by the estimated parameter coeffi-
ient for the selected value attribute. Two value attributes were
sed for this analysis: 1) predictive ability, which is measuring a
hange of 1%, and 2) turnaround time, which is measuring a
hange in terms of the number of days. The MRS results were
ompared from the patient and professional sample. In addition,
ootstrapping was used to estimate 95% confidence intervals for
he MRS. This allows a direct comparison of the relative size of
he MRS, but note that the absolute size of the MRS will depend
n whether dummy or effects coding is used [39].
esults
he analysis included all completed questionnaires. A com-
leted questionnaire was defined as at least 50% of the choice
uestions (eight questions) being completed (10 patients and
Table 3 – Health care professionals characteristics.
Hospital doctors
(n84)
Years qualified* Mean 23.1
(8 to 34)
Specialty
Gastroenterology 41 (50%)
Rheumatology 22 (27%)
Renal medicine 1 (1%)
Dermatology 18 (22%)
Other (not named) 1 (1%)
Ever used a pharmacogenetic test
Yes 67 (80%)
Missing data 1 (1%)
Ever prescribed, dispensed, or educated a
patient about azathioprine?
Yes 80 (94%)
Missing data 0
Do not want to answer personal questions 13 (15%)
Have had a pharmacogenetic test
(self-reported)
Yes 0
No 69 (81%)
Don’t know 2 (2%)
Missing data 1 (1%)
Ever reacted badly to a medicine
(self-reported)
Yes 18 (21%)
No 51 (60%)
Missing data 3 (4%)
Friends or family ever reacted badly to a
medicine (self-reported)
Yes 12 (14%)
No 58 (68%)
Missing data 1 (1%)
Ever taken azathioprine (self-reported)
Yes 0
No 70 (82%)
Missing data 2 (2%)* Missing data: n  2 hospital doctors; n  3 GPs; n  1 pharmacist; n  61 health-care professionals returned uncompleted question-
aires). One further questionnaire was excluded because the
ealth-care professional answered only one choice question.
he final analysis comprised 159 (18 rheumatology and 141
astroenterology) patients and 138 health-care professionals
84 consultants, 31 GPs, 13 nurses, 10 pharmacists, and 2 cli-
icians with joint hospital-general practice posts who were
erged with the consultant sample for the analysis). This ac-
orded with response rates of 50% and 34%, respectively, for
atients and health-care professionals. Nine (6%) of the pa-
ients and 24 (17%) of the health-care professionals did not
omplete all of the binary choice questions. Eight of the
ealth-care professionals did not answer all the binary choice
uestions because four questions were on one page of the
urvey, which appeared to have been turned over in error.
haracteristics of respondents
ables 2 and 3 summarize the characteristics of the patient
nd the health-care professional samples, respectively. The
GPs
(n31)
Nurse
(n13)
Pharmacist
(n10)
Total
(n138)
ean 25.6
(10 to 38)
Mean 21.3
(6 to 30)
Mean 22.7
(9 to 39)
Mean 23.2
(6 to 39)
NA 9 (69%) 0 50 (36%)
2 (15%) 1 (10%) 25 (18%)
0 3 (30%) 4 (3%)
0 1 (10%) 20 (14%)
2 (15%) 5 (50%) 8 (6%)
1 (3%) 10 (77%) 0 79 (57%)
0 0 0 1 (1%)
28 (90%) 10 (77%) 9 (90%) 127 (91%)
1 (3%) 1 (8%) 1 (10%) 3 (2%)
2 (7%) 1 (8%) 1 (10%) 17 (12%)
0 0 1 (10%) 1 (1%)
29 (94%) 12 (92%) 8 (80%) 118 (96%)
0 0 0 2 (1%)
0 0 0 1 (1%)
5 (16%) 2 (15%) 1 (10%) 26 (21%)
24 (77%) 9 (69%) 8 (80%) 92 (75%)
2 (2%) 1 (8%) 0 6 (5%)
5 (16%) 2 (15%) 0 19 (16%)
23 (74%) 10 (77%) 9 (90%) 100 (82%)
0 0 0 1 (1%)
0 0 0 0
28 (90%) 12 (92%) 9 (90%) 119 (98%)
0 0 0 2 (1%)Mtotal.
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128 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4ean age of the patients was 45.8 years old (range, 17–82 years
ld) with 90 women (56%).
The patients in the sample had a range of levels of educa-
ion and employment status. The majority of the patients had
astroenterological conditions and had taken azathioprine.
ome of the patients (4%) reported never taking azathioprine.
nterestingly, one-fifth of the patient (21%) sample said they
id know they had been given a pharmacogenetic test, even
hough the trial design expected patients to be “blinded” to the
se of the test, but almost half of the sample were not sure.
early half of the patients reported having experienced a side
ffect to a medicine (47%) and around one-half (51%) of the
atients said they had a side effect from azathioprine with 6%
f patients having a serious side effect requiring hospitaliza-
ion. Some patients (17%) reported that their friends or family
ad experienced side effects from medicines. The majority of
atients (86%) still reported taking the azathioprine at the
ime of completing the questionnaire, in accordance with the
nstructions prescribed by their doctor.
The health-care professional sample was a mix of disci-
lines but the largest proportion were hospital-based clini-
ians working in gastroenterology, who had experience with
harmacogenetic testing and prescribing azathioprine (29%).
his reflected the sampling frame for the study. The majority
f the sample comprised health-care professionals with over
0 years of experience in practice. The health-care profession-
ls were also asked whether they would be willing to answer
uestions about their personal experience of taking medicines
nd most (88%) agreed to answer this question. Some health-
are professionals reported experience of a side effect either
hemselves (19%) or in their friends and family (14%). None of
he health-care professionals had taken azathioprine. One
harmacist reported having had a pharmacogenetic test, but
id not name which one.
agnitude and statistical significance of attributes
able 4 shows the estimated coefficients for the base-case
Table 4 – Random effects probit regression model (time an
Attribute Patient
Coefficient Standard error
Information-low 0.115 0.037
Information-mod 0.183 0.037
Information-high 0.347 0.035
Predictive accuracy 0.033 0.001
Sample-wash 0.067 0.036
Sample-finger 0.019 0.036
Sample-swab 0.039 0.034
Turnaround time 0.018 0.002
Explanation-pharmacist 0.385 0.039
Explanation-hospital Dr. 0.264 0.040
Explanation-nurse 0.060 0.033
Constant 0.214 0.038
Number of obs  2521
Number of groups  159
Wald chi2(11)  741.78
Log likelihood  1188.8nalysis of the patient and health-care professional data. The tstimated coefficients for the two value attributes, predictive
ccuracy and turnaround time, both had the expected sign
nd were statistically significant with patients and health-
are professionals preferring a higher predictive accuracy and
horter turnaround times for the test result. Patients had
trong preferences for the amount of information being given
efore taking the test and for who explained the test result,
ith statistically significant coefficients for each level of the
ttribute. The negative sign on the coefficient for the first in-
ormation effects code suggests patients would prefer to have
o information rather than low levels of information. The pos-
tive signs on the other coefficients for information provision
hen indicate that patients go on to prefer high compared to
oderate levels of information. Two of the three estimated
oefficients for information were small and failed to reach
tatistical significance for the health-care professional sam-
le, which indicates this attribute was not a strong driver for
heir preferences, but they did prefer to give high rather than
oderate levels of information. Both patients and health-care
rofessionals indicated that they did not want a pharmacist to
xplain the test result but would prefer a hospital doctor. Nei-
her patients nor health-care professionals had significant
references for the method of how the DNA sample was col-
ected. The constant term specified in the model was statisti-
ally significant, which indicates there was some left- or right-
and side bias in the responses, with more respondents
ndicating a preference for option B rather than A.
esting for non-linear effects of the value attributes
he model estimated for the base-case analysis assumed that
he two quantitative attributes were linear and continuous.
his assumption was tested by specifying a random effects
robit model with the two value attributes included using ef-
ects coding. Table 5 shows the results from this analysis. It
an be seen that the linear assumption is reasonable for both
ttributes. However, the sign of moving between the lower
evels of the attributes is not consistent with a priori expecta-
dictive accuracy linear).
Health care professional
P value Coefficient Standard error P value
0.002 0.020 0.048 0.673
0.000 0.044 0.046 0.342
0.000 0.202 0.045 0.000
0.000 0.049 0.002 0.000
0.062 0.062 0.045 0.171
0.607 0.013 0.046 0.785
0.254 0.011 0.041 0.781
0.000 0.023 0.003 0.000
0.000 0.215 0.050 0.000
0.000 0.299 0.048 0.000
0.070 0.004 0.041 0.919
0.000 0.288 0.041 0.000
Number of obs  2153
Number of groups  138
Wald chi2(11)  649.41
Log likelihood  844.9d preions. Figures 2 and 3 show plots of the estimated coeffi-
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lso indicate that a linear assumption seems reasonable. In
ddition, a more formal test of linearity was conducted by
dding a quadratic term into the model for predictive accuracy
Table 5 – Random effects probit regression model (all attrib
Attribute Patient
Coefficient Standard error
Information-low 0.119 0.037
Information-mod 0.151 0.040
Information-high 0.353 0.037
Predictive accuracy-60 0.293 0.038
Predictive accuracy-85 0.373 0.035
Predictive accuracy-90 0.656 0.036
Sample-wash 0.082 0.036
Sample-finger 0.019 0.039
Sample-swab 0.040 0.038
Turnaround time-7 0.114 0.037
Turnaround time-14 0.103 0.036
Turnaround time-28 0.262 0.038
Explanation-pharmacist 0.391 0.040
Explanation-hospital Dr. 0.282 0.041
Explanation-nurse 0.042 0.034
Constant 0.199 0.039
Number of obs  2521
Number of groups  159
Wald chi2(15)  745.67
Log likelihood  1179.8
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C
ig. 2 – (A) Predictive ability (health-care professionals). (B) T
bility (patients). (D) Turnaround time (patients).nd turnaround time, separately in both patient and profes-
ional data sets. The quadratic term for predictive accuracy
as not statistically significant (P  0.507). The quadratic
erm for turnaround time was statistically significant for
effects coded).
Health care professional
P value Coefficient Standard error P value
0.001 0.013 0.049 0.799
0.000 0.010 0.060 0.863
0.000 0.213 0.055 0.000
0.000 0.494 0.055 0.000
0.000 0.705 0.046 0.000
0.000 0.888 0.049 0.000
0.023 0.098 0.052 0.057
0.626 0.057 0.058 0.332
0.293 0.018 0.052 0.736
0.002 0.129 0.050 0.010
0.004 0.127 0.047 0.006
0.000 0.349 0.054 0.000
0.000 0.250 0.056 0.000
0.000 0.340 0.060 0.000
0.208 0.006 0.047 0.898
0.000 0.299 0.049 0.000
Number of obs  2153
Number of groups  138
Wald chi2(15)  614.33
Log likelihood  841.3
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130 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4oth the patient (P 0.035) and professional (P 0.033) data,
uggesting turnaround time is non-linear. However visual
nspection of the data indicated that there was not a strong
eviation from the linear assumption, and an average MRS
omputed using the linear assumption is a reasonable sum-
ary of the behavior.
est for internal validity
even (4%) patients, all with gastroenterological conditions,
ailed the dominance check question included as a test for inter-
al validity. One health-care professional failed the dominance
heck question. In addition, eight health-care professionals did
ot answer the dominance question because the page of the
urvey appeared to have been turned over in error. The impact of
ncluding the respondents who “failed” the internal validity test
n the final analysis was explored by running two models with
he responses included and then removed from the analysis.
his analysis indicated that removing the respondents who
failed this test” did not have any impact on the analysis and so
heir responses were included in the final sample.
est for dominant preferences
hree attributes were examined individually for evidence of
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A
B
ig. 3 – (A) Plot of patient versus health-care professionals’
stimated coefficients (all effects coding). (B) Plot of patient
ersus health-care professionals’ estimated coefficients
time and predictive accuracy linear).ominant preferences in the responses. The predictive accu- 0acy attribute showed the strongest evidence for the presence
f dominant preferences in the sample, and 15 patients (9%)
nd 14 health-care professionals (10%) appeared to exhibit a
ominant preference for “predictive accuracy”. If the ranking
ata (from section 2 of the survey) were also used, then these
gures were reduced to 13 patients and 13 health-care profes-
ionals showing dominant preferences. Three patients (2%)
ad a dominant preference for “information provided,” which
educed to two patients if the ranking data were also consid-
red. No patients or health-care professionals had a dominant
reference for “turnaround time,” The model was re-run ex-
luding the data for dominant preferences on “predictive ac-
uracy,” but this did not appreciably affect the estimated co-
fficients and all data were used in the final analysis.
omparing preferences
he Swait and Louviere [38] test confirmed that the estimated
oefficients were different for patients and health-care profes-
ionals. Table 6 summarizes the estimated MRS for both sam-
les. The marginal rates of substitution were only calculated
sing the results estimated for the unadjusted model, which
id not include covariates representing the characteristics of
he respondents and their prior experience of pharmacoge-
etic testing. Patients and health-care professionals had sim-
lar preferences for predictive accuracy of the test and were
illing to wait 1.8 and 2.2 days, respectively, for a 1% improve-
ent. Patients preferred to obtain more information when
eing told about the purpose of the pharmacogenetic test and
ere willing to wait 19.3 days compared to 8.9 days for health-
are professionals for high levels of information provision. In
eneral, patients had stronger preferences for whom would
rovide the explanation about the test results. Neither pa-
ients nor health-care professionals would want a pharmacist
o explain the test result but patients showed stronger prefer-
nces by not wanting to give up 11.6% in predictive ability, or
ait an extra 21.4 days for a result, compared to 4.4% and 9.5
ays for the health-care professionals. Both patients and
ealth-care professionals indicated they wanted the hospital
octor to provide the result with similar strengths (willing to
ive up 7.9% and 6.1% in predictive ability and wait extra 14.7
ays and 13.2 days, respectively). Interestingly, patients indi-
ated they would want the GP to provide the test result but the
ize of the estimated model parameter suggests, health-care
rofessionals indicated that they would prefer them not to,
ut this finding was not a significant preference. Neither pa-
ients nor health-care professionals indicated strong prefer-
nces for a nurse to provide the explanation about the test
esults.
nfluence of respondent characteristics
he potential impact of respondent characteristics on pa-
ients’ and health-care professionals’ preferences was ex-
lored by including interaction terms of the attribute and
haracteristic in the model. In the patient sample, the pre-
enting condition of the patient had an impact on preferences
or the level of information they preferred before the test (P 
.001. Preferences for the predictive ability were affected by
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131V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4hether or not patients reported that they had been given a
harmacogenetic test before (P 0.008) and whether they had
xperienced a side effect from a medicine (P  0.007). Prefer-
nces for the level of information (P  0.001) and predictive
ccuracy (P  0.000) were influenced by the discipline of the
ealth-care professional.
iscussion
his article presents the results from the first stated prefer-
nce study to identify and explore the attributes of a pharma-
ogenetic testing service and makes a direct comparison of
he preferences of a patient and health-care professional sam-
le. The study focused on five attributes of a pharmacogenetic
ervice: how much information should be given prior to the
est; method for collecting the DNA-sample; predictive accu-
acy (effectiveness) of the test; waiting time for the test result;
nd who should explain the test result. The patients surveyed
n this study had different preferences compared with the
ealth-care professional sample, especially in terms of infor-
ation provision. In particular, they placed more importance
n having more information before the test and had stronger
references for whom should provide the test result, com-
ared with health-care professionals. In practice, specialist
urses often provide test results to patients, especially those
ith chronic conditions, such as rheumatoid arthritis or
rohn’s disease, but this patient sample indicated that they
ould prefer a clinician to explain a pharmacogenetic test,
eteris paribus. Patients would be happy with a GP explaining
he test result, but there was weak evidence, from the esti-
ated model, that other health-care professionals did not
gree that this was appropriate. It may seem counter intuitive
or health-care professionals to not want a GP to provide test
esults. This may be so, but this view could also be explained
Table 6 – Marginal rates of substitution using predictive ab
Attribute Patients
Coef MRS predictive
(%) [95% CI]†
MR
(d
Predictive accuracy 0.033‡ — 1.
Turnaround time 0.018‡ 0.5 [0.7 to 0.4]
Information-none* 0.415 12.5 [14.6 to 10.4] 23.
Information-low 0.115‡ 3.5 [5.8 to 1.2] 6.
Information-mod 0.183‡ 5.5 [3.4 to 7.7] 10.
Information-high 0.347‡ 10.4 [8.3 to 12.6] 19.
Sample-blood* 0.047 1.4 [3.4 to 0.6] 2.
Sample-wash 0.067 2.0 [0.2 to 4.2] 3.
Sample-finger 0.019 0.6 [1.6 to 2.7] 1.
Sample-swab 0.039 1.2 [3.0 to 0.7] 2.
Explanation-GP* 0.061 1.8 [0.0 to 3.7] 3.
Explanation-pharmacist 0.385‡ 11.6 [14.1 to 9.2] 21.
Explanation-hospital Dr. 0.264‡ 7.9 [5.4 to 10.5] 14.
Explanation-nurse 0.060 1.8 [0.1 to 3.8] 3.
* Calculated by assuming estimate for effects coded omitted variable
† Confidence intervals estimated using the bootstrap method.
‡ Statistically significant at P  0.05.hat health-care professionals may be indicating concerns that GPs do not currently have sufficient knowledge and con-
dence to report test results back to patients and advise on
ow to modify their azathioprine prescription. Further re-
earch, possibly using qualitative methods to understand the
easoning behind such preferences, is required to explore this
nding in more depth. Neither group would want a pharma-
ist to explain the test result. Patients and health-care profes-
ionals had similar preferences for predictive accuracy of the
est and turnaround time.
Time and predictive accuracy proved to be key attributes in
model of a pharmacogenetic testing service and were also
ncluded as value attributes in the design of the DCE to allow
or estimation of MRS and comparison between the prefer-
nces of patients and health-care professionals. The esti-
ated MRS is the mean preferences for the study sample, and
e did not account for heterogeneity in preferences in the
nalysis. Further work is necessary to understand if there are
ignificantly different preferences between sub-groups of the
ample — for example, between the different disciplines of
ealth-care professionals. Using time and predictive accuracy
o estimate a single MRS requires the assumption that the
ttribute is linear and continuous. This assumption was found
o be valid for predictive accuracy, within the constraints of
sing a percentage as a metric. Although the analysis indi-
ated that turnaround time was not truly linear, the amount of
on-linearity was small and a single MRS is a reasonable rep-
esentation over the range of values investigated.
A similar pattern in turnaround time was observed in both
atient and health-care professional samples. Neither group
anted a turnaround time of 2 days, but equally would not
ant to wait for long turnaround times of more than 7 days.
his has some practical relevance because it potentially alters
he service delivery model. Both patients, with the experience
f living with a chronic condition, and health-care profession-
ls managing patients with a chronic disease, would realize
and turnaround time as value attributes.
Health care professionals
naround
[95% CI]†
Coef MRS
predictive (%)
[95% CI]†
MRS turnaround
(days) [95% CI]†
.3 to 1.4] 0.049‡ — 2.2 [2.6 to 1.7]†
— 0.023‡ 0.5 [0.6 to 0.4] —
0 to 30.2] 0.266 5.5 [7.0 to 3.9] 11.8 [7.5 to 16.0]
to 10.8] 0.020 0.4 [1.6 to 2.4] 0.9 [5.2 to 3.4]
4.9 to 5.5] 0.044 0.9 [0.8 to 2.6] 1.9 [5.5 to 1.6]
4.7 to 13.9] 0.202‡ 4.2 [2.4 to 5.9] 8.9 [12.6 to 5.3]
.2 to 6.4] 0.061 1.2 [2.9 to 0.4] 2.7 [1.1 to 6.4]
.8 to 0.30] 0.062 1.3 [0.5 to 3.0] 2.7 [6.5 to 1.0]
.0 to 3.0] 0.013 0.3 [2.1 to 1.5] 0.6 [3.5 to 4.6]
.4 to 5.8] 0.011 0.2 [1.3 to 1.7] 0.5 [3.8 to 2.8]
.9 to 0.0] 0.088 1.8 [3.4 to 0.2] 3.9 [0.4 to 7.4]
3 to 28.6] 0.215‡ 4.4 [6.4 to 2.4] 9.5 [4.5 to 14.5]
1.2 to 8.2] 0.299‡ 6.1 [4.1 to 8.1] 13.2 [19.1 to 7.4]
.0 to 0.2] 0.004 0.1 [1.5 to 1.7] 0.2 [3.7 to 3.3]
ulated by assuming  1 (sum of estimated levels).ility
S tur
ays)
8 [2
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calchat this appointment system would not work in practice.
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132 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4herefore, 1 week is a more practical and feasible turnaround
ime for this pharmacogenetic test for a chronic disease. How-
ver, it is likely, that a shorter turnaround time may be pre-
erred for a pharmacogenetic test that is used to inform pre-
cribing in acute conditions, such as testing to inform
arfarin prescribing to prevent thromboembolic disease [40].
Herbild et al. [41] explored “willingness to pay” for a phar-
acogenetic test using a four attribute web-based DCE to elicit
references for the treatment of depression in terms of:
hanges in drug treatment, time with dosage adjustments due
o adverse side effects and/or lack of effects, cost of pharma-
ogenetic testing, and the probability of benefits from phar-
acogenetic testing. Findings suggest that if diagnosed with
epression, peoples’ willingness to pay for pharmacogenetic
esting exceed price, as long as there is a 10% probability for
mprovements in treatment. This study provided useful infor-
ation on the uptake of pharmacogenetic tests, but it did not
ndicate “how” the pharmacogenetic testing service is best
rovided.
This current study has provided information that is partic-
larly pertinent in this era of demand for patient-led services
nd patient choice [42,43]. Patients in this study indicated that
nformation provision is a key component of a pharmacoge-
etic testing service, but health-care professionals were less
oncerned about information provision compared to predic-
ive test accuracy and turnaround time. Importantly, patients
ere clear that they would prefer to receive no information at
ll compared with low levels of information. Health-care pro-
essionals agreed with this which has implications for service
elivery in that providing low, and potentially, insufficient
evels of information is perceived to be much less useful than
ore detailed information. Other DCE studies in health care
ave highlighted the importance to patients of the provision
f information in the delivery of health-care services [44,45]. A
ecent qualitative study also supported that patients demand
ducated and knowledgeable health-care professionals to ex-
lain why they should have a pharmacogenetic test and how
he test results would be used; trust and familiarity were im-
ortant to patients, and health-care professionals empha-
ized a need for an integrated service [26]. A number of
ommentators have questioned whether health-care profes-
ionals are ready to deliver pharmacogenetic testing services
n terms of their education and current knowledge base
46,47]. Pharmacogenetic testing services are not currently es-
ablished as part of mainstream health-care services, and
ome professional bodies [25] have started to address the core
kills that would be required to safely and effectively deli-
er such services. This study provides further support that
chools of medicine, nursing, and pharmacy need to include
eaching that covers the scientific basis of using basic genetic
ata to inform prescribing together with the practical impli-
ations of delivering a pharmacogenetic service as a part of
he core curricula for undergraduate students.
Marginal rates of substitution were calculated using pre-
ictive ability and turnaround time as the value attributes to
llow direct comparison between the patient and health-care
rofessional preferences. A cost attribute was considered, but
xcluded due to the objections of the ethics committee. In-
luding a cost attribute would have allowed an estimation of aarginal willingness to pay for each service attribute. It is also
cknowledged that the study sample comprised NHS patients
nd staff who are familiar with health care that is free at the
oint of access. The study sample comprised patients who
ad been recruited to an RCT of the TPMT test and clinicians
ho had some role in providing the test as part of the RCT. It
ould be assumed that these were individuals who were fa-
iliar with the test and may have brought extra information,
ot included in the design in terms of attributes and levels
resented, to the stated preference exercise. However, the pa-
ients were blinded to the randomization process and did not
now whether they were given the TPMT test during the trial;
lthough when questioned, one-fifth of the patients reported
nowing that they had been given a pharmacogenetic test.
linicians could be classified as being familiar with the test
ut the respondents were instructed to only use the attributes
escribed to make their choices. However, there is still a pos-
ibility that the health-care professionals, in particular, were
sing extra information that was not controlled for in the ex-
eriment, when making their choices [25].
A higher proportion of patients compared with health-care
rofessionals, and GPs in particular, returned completed
uestionnaires, which could suggest that patients were more
ngaged in the study as they were more willing to answer the
urvey questions. The response rate for the health-care pro-
essionals was disappointing and is a limitation of this study.
he available sample frame and resulting sample size for this
CE meant that the design could only include main effects
nd did not allow estimation of two-factor interactions. The
rimary purpose of this DCE was to compare the preferences
f patients and health-care professionals, and including main
ffects in the design was sufficient for this purpose. Extending
he survey to a larger sample frame and size would allow the
CE design to be modified and include two-factor interac-
ions, but this design would require more scenarios. Further-
ore, Lanscar and Louviere [37] acknowledge that the true
ature of the bias from using designs that do not use interac-
ions is unknown and is a potential topic for future research.
This study included responses from the respondents who
failed” the dominance test. There were relatively few such
ases and the parameter estimates were not substantially dif-
erent when these respondents were excluded from the anal-
sis. Including respondents who behave in a dominant man-
er can potentially lead to bias in the parameter estimates, but
he dominance tests may not reliably identify these individu-
ls. San Miguel et al. [33] suggested that failing such a test was
irectly related to the characteristics of the respondent and,
herefore, removing them from the analysis can introduce
ystematic bias due to only selecting respondents who pass
he dominance test [25]. Further research is necessary to un-
erstand whether it is better to accept the bias of a sample
ontaining “irrational” respondents compared with a sample
hat may be prone to selection bias because of removing spe-
ific individuals.
This study focused on understanding the nature of prefer-
nces for how a pharmacogenetic testing service should be
elivered rather than identifying attributes that would affect
he uptake of a pharmacogenetic test. A pharmacogenetic test
ims to provide quantitative information about the potential
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133V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 2 1 – 1 3 4or risk reduction by predicting which patients would experi-
nce neutropenia. This is a necessary topic of further research
o understand how current and future patients value the po-
ential risk reduction offered by pharmacogenetic testing to
etect a specific side effect to a medicine.
The effect of respondent characteristics on their prefer-
nces was explored by including interaction terms in a model.
his analysis identified potentially important influences of re-
pondent characteristics on preferences such as presenting
ondition of the patient, whether or not patients reported that
hey had been given a pharmacogenetic test before, and
hether they had experienced a side effect from a medicine.
references for the level of information and predictive accu-
acy were influenced by the discipline of the health-care pro-
essional. This analysis was only exploratory and starts to
dentify heterogeneity in preferences by looking at one poten-
ial effect of differences in preferences between individuals. A
ifferent experimental design and larger sample size for each
f the discipline sub-groups would be required to further ex-
lore heterogeneity in preferences. Hole [48] appropriately
uggests that individuals are likely to have different prefer-
nces (taste heterogeneity) and some of this preference heter-
geneity is not related to personal characteristics of the re-
pondents that can be observed. Therefore, alternative model
pecifications have been suggested as necessary to under-
tand heterogeneity in preferences, such as the mixed logit
odel, which is a generalization of the multinomial logit
odel that accounts for two aspects 1) the panel structure of
he data, and 2) allows for preference heterogeneity across
ndividuals and allows parameters to vary randomly across
ndividuals [49]. In a binary choice model, which is applicable
or this study, random effects can be used to account for the
anel structure of the data but using random effects in a probit
or logit) model does not allow you to estimate preference het-
rogeneity. However, there have been valid criticisms of using
ixed logit to account for preference heterogeneity. Fiebig et
l. [50] suggest that the generalized-multinomial logit model
hould be used to account for heterogeneity in preferences
ecause, unlike the mixed logit and latent class models, the
eneralized-multinomial logit takes scale heterogeneity into
ccount that can then identify “extremes” of consumers, from
hose who have almost lexicographic preferences to those
ho show very random behavior in their choices. Other meth-
ds, such as estimating individual-level models, have been
uggested but these require very large data sets if the data are
erived from DCE designs. Alternative experimental designs,
uch as best-worse scaling, are recommended as viable alter-
atives to look at the preferences of individual decision-mak-
rs [51].
onclusion
his DCE determined and compared the preferences of pa-
ients and health-care professionals of TPMT testing, which is
n example of a pharmacogenetic testing service providing
nformation about azathioprine prescribing. Patients and
ealth-care professionals had similar preferences for predic-
ive accuracy of the test and turnaround time for the test re-ults. There were clear differences in the patients’ and health-
are professionals’ preferences for information provision. The
ndings from this study provide health-care policy makers
ith clear evidence that patients demand accurate and timely
nformation about the reason to have a pharmacogenetic test,
nd what the test results mean, from health-care profession-
ls. In contrast, health-care professionals appear to focus
ore exclusively, or entirely, on the predictive accuracy and
aiting time for a test result.
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